Amolyt Pharma is a biopharmaceutical company focused on developing treatments for hypoparathyroidism, a rare endocrine disorder. The company is developing eneboparatide, a novel parathyroid hormone receptor 1 (PTHR1) agonist, which has demonstrated promising results in clinical trials.

Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.

Novo Ventures

Sham Innovation Santé

ATEM Capital Fund LP

Kurma Partners

EQT life science

Mass General Brigham Ventures

OrbiMed

Pontifax

Credit Agricole Entreprises

Eurazeo

Sectoral Asset Management

Bpifrance

Sofinnova Partners

Tekla Capital Management

Intermediate Capital Group

CTI Life Sciences Fund

Andera Partners

Amolyt Pharma

COM:AMOLYTPHARMA

Amolyt Pharma

Analysis Not Available